NCT03928158View on ClinicalTrials.gov

LCZ696 in Advanced LV Hypertrophy and HFpEF

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 31, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions
Heart FailureEssential Hypertension
Interventions
DRUG

LCZ 696

50-100-200 mg tablet

DRUG

Valsartan

40-80-160 mg tablet

Trial Locations (1)

121552

National Medical Research Center for Cardiology, Moscow

All Listed Sponsors
lead

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

OTHER_GOV

NCT03928158 - LCZ696 in Advanced LV Hypertrophy and HFpEF | Biotech Hunter | Biotech Hunter